Based on top-line efficacy results from two pivotal Phase 3 trials Eli Lilly And Co (NYSE:LLY) has decided to discontinue the Phase 3 development program for Olumiant in systemic lupus erythematosus (SLE).
- In SLE-BRAVE-I, the baricitinib 4-mg oral dose met the primary endpoint, demonstrating a statistically significant reduction in disease activity compared to placebo.
- The SLE-BRAVE-II study, which also studied adults with active lupus, did not meet the primary endpoint of reduction in disease activity.
- Key secondary endpoints were not met in either study.
- Lilly is working with investigators to appropriately conclude the Phase 3 SLE long-term extension trial, designed to evaluate the long-term safety and efficacy of Olumiant over three years in adults.
- Eli Lilly also expects the FDA to decline the expanded use of baricitinib as a treatment for adults with moderate-to-severe eczema.
- "At this point, the company does not have alignment with the FDA on the indicated population," the drugmaker said.
- Given the Agency's position, there is a possibility that this could lead to a Complete Response Letter.
- Olumiant, a once-daily, oral JAK inhibitor was discovered by Incyte Corporation (NASDAQ:INCY) and licensed to Lilly
- Price Action: LLY shares are up 1.39% at $240.01 during the market session on the last check Friday.
